Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer
European Urology Oncology, giugno 2021

2) Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma
Cancers, 30 novembre 2021

3) Inflammatory metabolic profile of South African patients with prostate cancer
Cancer & Metabolism, 3 agosto 2021

4) EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer
Nature Communications, 6 luglio 2021

5) Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Nature Communications, 2 febbraio 2021

6) Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer
Communications Biology, 26 gennaio 2021

7) Erratum: Mapelli, S.N., et al. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers 2020, 12, 176
Cancers, 14 ottobre 2020

8) A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors)
Cancers, 10 gennaio 2020
Giuseppina Carbone
is currently collaborating with
Istituto Oncologico di Ricerca (IOR) (Rif. IOR)
Via Francesco Chiesa 5
6500 Bellinzona
Giuseppina Carbone
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Prostate Cancer Biology
as Group Leader [Rif. 55110]